Biologic Therapies for Moderate to Severe Asthma in the Pediatric Population: A Practice Update

Author:

Tolomeo Concettina1ORCID

Affiliation:

1. Yale University, School of Medicine, Section of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine, New Haven, CT, USA

Abstract

Introduction Asthma is a common childhood condition. Up until recent years, the mainstay of long-term control treatment has been inhaled corticosteroids. While inhaled corticosteroids are very effective for most children with asthma, with the introduction of biologic therapies, additional options now exist for children with uncontrolled moderate to severe asthma. Purpose The purpose of this Practice Update is to provide nursing professionals with a summary of the biologic therapies currently available for the pediatric population and, to describe when they are indicated for inclusion in the plan of care for children with moderate to severe asthma. Conclusion By properly diagnosing asthma, and, selecting and administering appropriate asthma therapies, nursing professionals can help children with moderate to severe asthma lead healthy and active lives.

Publisher

SAGE Publications

Subject

General Nursing

Reference18 articles.

1. AstraZeneca (2021a). Benralizumab: Fasenra prescribing information. AstraZeneca.

2. AstraZeneca. (2021b). Tezepelumab: Tezspire full prescribing information. AstraZeneca.

3. Which Child with Asthma is a Candidate for Biological Therapies?

4. Centers for Disease Control and Prevention (CDC) (N.D.a). Asthma-related missed school days among children aged 5–17 years.  https://www.cdc.gov/asthma/asthma_stats/missing_days.htm

5. Centers for Disease Control and Prevention (CDC) (N.D.b). Asthma severity among children with current asthma. https://www.cdc.gov/asthma/asthma_stats/severity_child.htm

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Moderate asthma: burden, mechanisms and therapeutic perspectives;Current Opinion in Allergy & Clinical Immunology;2023-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3